SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

CGTX.O (CGTX.O) News

Track canonical SquawkNews coverage tagged to CGTX.O, CGTX.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol CGTX.O Asset market Sector Markets 90 days 1 Updated Sep 29, 2026, 11:32 AM UTC Open live news feed
M Cognition Therapeutics schedules Type C FDA meeting on zervimesine Phase 3 DLB endpoints Cognition Therapeutics scheduled a Type C meeting with the FDA for October 20, 2026 to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB. EQUITY | Sep 29, 2026, 11:32 AM UTC